nach oben

Erschienen in:

01.11.2008 | Biological Child and Adolescent Psychiatry - Original Article

Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone

verfasst von: Christian Fleischhaker, Philip Heiser, Klaus Hennighausen, Beate Herpertz-Dahlmann, Kristian Holtkamp, Claudia Mehler-Wex, Reinhold Rauh, Helmut Remschmidt, Eberhard Schulz, Andreas Warnke

Erschienen in: Journal of Neural Transmission | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate long-term weight gain associated with clozapine, olanzapine, and risperidone treatment and its clinical risk factors in children and adolescents. At four child and adolescent psychiatric departments, the weight and body mass index of initially hospitalized patients (aged 9.0–21.3 years) treated with clozapine (n = 15), olanzapine (n = 8), and risperidone (n = 10) were prospectively monitored for 45 weeks. Clinical risk factors (age, gender, baseline weight, dosage, drug-naivety) were tested for their association with weight gain in the three groups. All three groups experienced significant weight gain between baseline and endpoint. The absolute and percentage average weight gains were significantly higher for the olanzapine group (16.2 ± 8.8 kg; 30.1 ± 18.9%) than for the clozapine (9.5 ± 10.4 kg; 14.8 ± 15.8%) and the risperidone (7.2 ± 5.3 kg; 11.5 ± 6.0%) groups. Olanzapine is associated with extreme long-term weight gain in children and adolescents that, in addition, is much higher than that expected in adults. Clozapine and risperidone are associated with a less marked weight gain in children and adolescents but also much higher than that expected in adults. These differences may affect compliance with medication and health risk.

Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 Suppl 7:22–31PubMed

Allison DB, Mentore JL, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696PubMed

Aman MG, De Smedt G, Derivan A et al (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337–1346PubMedCrossRef

Armenteros JL, Whitaker AH, Welikson M et al (1997) Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 36:694–700PubMedCrossRef

Brady KT (1989) Weight gain associated with psychotropic drugs. South Med J 82:611–617PubMed

Buitelaar JK (2000) Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 10:19–26PubMed

Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P et al (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239–248PubMed

Bustillo JR, Buchanan RW, Irish D et al (1996) Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 153:817–819PubMed

Cesena M, Gonzalez-Heydrich J, Szigethy E et al (2002) A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol 12:337–345PubMedCrossRef

Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates, Hillsdale, NJ

Csernansky JG, Okamoto A, Brecher M (1999) Risperidone vs haloperidol: Prevention of relapse in schizophrenia. Eur Neuropsychopharmacol 9:268

Dittmann RW, Meyer E, Freisleder FJ et al (2008) Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 18:54–69PubMedCrossRef

Findling RL, McNamara NK, Branicky LA et al (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509–516PubMedCrossRef

Findling RL, McNamara NK, Youngstrom EA et al (2003) A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 42:170–175PubMedCrossRef

Fleischhaker C, Heiser P, Hennighausen K et al (2006) Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol 16:308–316PubMedCrossRef

Fleischhaker C, Heiser P, Hennighausen K et al (2007) Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 114:273–280PubMedCrossRef

Frazier JA, Gordon CT, McKenna K et al (1994) An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:658–663PubMedCrossRef

Frazier JA, Meyer MC, Biederman J et al (1999) Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960–965PubMedCrossRef

Frazier JA, Biederman J, Tohen M et al (2001) A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239–250PubMedCrossRef

Gothelf D, Falk B, Singer P et al (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055–1057PubMedCrossRef

Gothelf D, Apter A, Reidman J et al (2003) Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 110:545–560PubMedCrossRef

Hellings JA, Zarcone JR, Crandall K et al (2001) Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11:229–238PubMedCrossRef

Horrigan JP, Barnhill LJ (1997) Risperidone and explosive aggressive autism. J Autism Dev Disord 27:313–323PubMedCrossRef

Kant R, Chalasani L, Chengappa KN (2002) The Use of Clozapine in Adolescents with Diagnoses Other Than Schizophrenia. Journal of Child and Adolescent Psychopharmacology 12:290

Kelly DL, Conley RR, Love RC et al (1998) Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8:151–159PubMedCrossRef

Kewley GD (1999) Risperidone in comorbid ADHD and ODD/CD. J Am Acad Child Adolesc Psychiatry 38:1327–1328PubMedCrossRef

Klimke A, Klieser E (1995) The atypical neuroleptic clozapine (Leponex)–current knowledge and recent clinical aspects. Fortschr Neurol Psychiatr 63:173–193PubMed

Krishnamoorthy J, King BH (1998) Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 8:107–113PubMed

Kromeyer-Hauschild K, Wabitsch M, Kunze D et al (2001) Perzentile für den Body-mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschrift Kinderheilkunde 149:807–818CrossRef

Kumra S, Frazier JA, Jacobsen LK et al (1996) Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090–1097PubMed

Kumra S, Jacobsen LK, Lenane M et al (1998) Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 37:377–385PubMedCrossRef

Leadbetter R, Shutty M, Pavalonis D et al (1992) Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149:68–72PubMed

Lombroso PJ, Scahill L, King RA et al (1995) Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 34:1147–1152PubMedCrossRef

Maagensen M, Aarkrog T (1999) Treatment of adolescent psychoses with olanzapine: A preliminary report. Nordic Journal of Psychiatry 53:435–438CrossRef

Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835PubMed

Marder SR, Essock SM, Miller AL et al (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334–1349PubMedCrossRef

Martin A, L’Ecuyer S (2002) Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 11:129–133PubMedCrossRef

Martin A, Landau J, Leebens P et al (2000) Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 10:259–268PubMed

Masi G, Cosenza A, Mucci M et al (2001) Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206–1214PubMedCrossRef

McCracken JT, McGough J, Shah B et al (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314–321PubMedCrossRef

McDougle CJ, Holmes JP, Bronson MR et al (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 36:685–693PubMedCrossRef

Michelson D, Amsterdam JD, Quitkin FM et al (1999) Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 156:1170–1176PubMed

Mozes T, Greenberg Y, Spivak B et al (2003) Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 13:311–317PubMedCrossRef

Mukherjee S, Decina P, Bocola V et al (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68–73PubMedCrossRef

National Institute of Mental Health (1976) Dosage record and treatment emergent symptom scale [DOTES]. In: Guy W (ed)ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, National Institute of Mental Health, Psychopharmacology Research Branch

Nemeroff CB (1997) Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58 Suppl 10:45–49PubMed

Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372–376PubMedCrossRef

Perry R, Pataki C, Munoz-Silva DM et al (1997) Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 7:167–179PubMed

Pi-Sunyer FX (1993) Medical hazards of obesity. Ann Intern Med 119:655–660PubMed

Potenza MN, Holmes JP, Kanes SJ et al (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37–44PubMedCrossRef

Ratzoni G, Gothelf D, Brand-Gothelf A et al (2002) Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337–343PubMedCrossRef

Remschmidt H, Hennighausen K, Clement HW et al (2000) Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 9 Suppl 1:9–19CrossRef

Rison RA, Stanton PK (1995) Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Neurosci Biobehav Rev 19:533–552PubMedCrossRef

Rockwell WJ, Ellinwood EH Jr, Trader DW (1983) Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J 76:1407–1412PubMed

Ross RG, Novins D, Farley GK et al (2003) A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 13:301–309PubMedCrossRef

Saklad SR, Ketchi CM, Amrung SA et al (2002) Gender differences in weight gain among adolescents started on atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology 12:288–289CrossRef

Schreier HA (1998) Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 8:49–59PubMed

Shaw P, Sporn A, Gogtay N et al (2006) Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721–730PubMedCrossRef

Sholevar EH, Baron DA, Hardie TL (2000) Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 10:69–78PubMed

Sikich L, Hamer RM, Bashford RA et al (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133–145PubMedCrossRef

Szigethy E, Wiznitzer M, Branicky LA et al (1999) Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 9:93–98PubMed

Van Bellinghen M, De Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5–13PubMedCrossRef

Wilkin TJ (2008) Diabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis. Pediatr Diabetes 9(3 Pt 2):23–32PubMedCrossRef

Wirshing DA, Boyd JA, Meng LR et al (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856–865PubMed

Wirshing DA (2004) Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 65 Suppl 18:13–26PubMed

Wirshing DA, Wirshing WC, Kysar L et al (1999) Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358–363PubMed

Zalsman G, Carmon E, Martin A et al (2003) Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 13:319–327PubMedCrossRef

Zuddas A, Di Martino A, Muglia P et al (2000) Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79–90PubMed

Titel: Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone
verfasst von: Christian Fleischhaker
Philip Heiser
Klaus Hennighausen
Beate Herpertz-Dahlmann
Kristian Holtkamp
Claudia Mehler-Wex
Reinhold Rauh
Helmut Remschmidt
Eberhard Schulz
Andreas Warnke
Publikationsdatum: 01.11.2008
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 11/2008
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-008-0105-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Simple Kortisontherapie stoppt primär progrediente Aphasie

Impostor-Syndrom häufig bei Hyperhidrose zu finden

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2008

A longitudinal study of schizophrenia- and affective spectrum disorders in individuals diagnosed with a developmental language disorder as children

Abnormal short latency afferent inhibition in early Alzheimer’s disease: a transcranial magnetic demonstration

Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson’s disease risk in a Polish PD cohort

Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol

Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies

Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer’s disease

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Simple Kortisontherapie stoppt primär progrediente Aphasie

Impostor-Syndrom häufig bei Hyperhidrose zu finden

Update Neurologie